D. Parmar

A. Sanyal, Z. Younes, M. Siddiqui, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist.

Kuldip B. Patel, H. Patel, A. Ghoghari, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)

H. Patel, A. Ghoghari, Mukul R Jain, 2022, Clinical pharmacology in drug development.

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis

L. Muñoz-Espinosa, R. Vuppalanchi, F. Shaikh, 2021, Clinical and translational gastroenterology.

Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.

N. Srinivas, D. Parmar, Shuchi N. Joshi, 2018, Clinical therapeutics.

Effectiveness of The PPAR Agonist Saroglitazar in Nonalcoholic Steatohepatitis: Positive Data from Preclinical & Clinical Studies

P. Jain, M. Krishnappa, D. Parmar, 2020 .

Saroglitazar is noninferior to feno ﬁ brate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial

R. Rodríguez‐Gutiérrez, D. Parmar, Jose G Gonzalez, 2022 .

Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)

D. Agrawal, S. D. De Silva, D. Parmar, 2022, American Journal of Nephrology.

Infusion of Pegylated Bovine Carboxyhemoglobin (PEG-COHb) Is Associated with Rapid Reversal of Progressive Acute Chest Syndrome in a Jehovah's Witness Patient with Hemoglobin SC Sickle Cell Disease

H. Meiselman, H. Forman, T. Coates, 2015 .

Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.

U. Batra, Sanjeev Kumar, D. Parmar, 2021, Clinical breast cancer.

A Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG).

Pankaj Kalita, S. K. Mendiratta, H. Patel, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reply to Agrawal and Kumar

Pankaj Kalita, S. K. Mendiratta, H. Patel, 2020, Clinical Infectious Diseases.

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

H. Chandra, J. Patel, K. Maithal, 2021, EClinicalMedicine.

A Food-Effect Study to Evaluate the Oral Bioavailability of Desidustat.

H. Patel, D. Parmar, K. Kansagra, 2022, Clinical pharmacology in drug development.

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

U. Kaul, K. Parmar, D. Parmar, 2019, Cardiovascular Diabetology.

Adult Vaccines

D. Parmar, 2007 .

Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.

J. McCarthy, D. Fidock, J. Möhrle, 2022, The Lancet. Infectious diseases.

Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC-MS/MS, a novel antimalarial compound.

J. Möhrle, H. Patel, A. Ghoghari, 2021, Bioanalysis.

Saroglitazar, A Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients with Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.

S. Sarin, A. Duseja, A. Sanyal, 2023, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients

A. Sanyal, M. Forsgren, M. Siddiqui, 2023, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.